Dexmedetomidine: Sedation, analgesia and beyond

Expert Opinion on Drug Metabolism and Toxicology

Volumn 4, Issue 5, 2008, Pages 619-627

  Chrysostomou, Constantinos ^a   Schmitt, Carol G ^a  

^a CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

Author keywords

2 adrenoreceptor agonists; Analgesia; Dexmedetomidine; Neuroprotection; Sedation

Indexed keywords

ALFENTANIL; ALPHA 2 ADRENERGIC RECEPTOR; ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; BENZODIAZEPINE; CATECHOLAMINE; CLONIDINE; DEXMEDETOMIDINE; FENTANYL; GLYCOPYRRONIUM BROMIDE; ISOFLURANE; LORAZEPAM; MIDAZOLAM; MORPHINE; PLACEBO; PROPOFOL; SEVOFLURANE; SUBSTANCE P; THIOPENTAL;

ADJUVANT THERAPY; ANALGESIA; ANEMIA; ATRIOVENTRICULAR CONDUCTION; BISPECTRAL INDEX; BLOOD PRESSURE; BRADYCARDIA; CATECHOLAMINE BLOOD LEVEL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; CRANIOTOMY; DELIRIUM; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EXCRETION; DRUG FEVER; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; GENERAL ANESTHESIA; GLYCOGEN METABOLISM; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HEART RATE; HUMAN; HYPERTENSION; HYPOTENSION; HYPOXIA; INTENSIVE CARE UNIT; KIDNEY FUNCTION; LIVER FUNCTION; LOADING DRUG DOSE; MOLECULAR WEIGHT; MONOTHERAPY; NAUSEA; NERVOUSNESS; NEUROPROTECTION; NONHUMAN; NORADRENALIN RELEASE; OLIGURIA; PARADOXICAL DRUG REACTION; PARTITION COEFFICIENT; PH; RECOMMENDED DRUG DOSE; RENAL PROTECTION; RESPIRATION DEPRESSION; RESTLESSNESS; REVIEW; SEDATION; SEIZURE; SIDE EFFECT; SINUS NODE DYSFUNCTION; SUPRAVENTRICULAR TACHYCARDIA; SYMPATHETIC FUNCTION; TACHYCARDIA; TRANQUILIZING ACTIVITY; VASOCONSTRICTION; VOMITING; WITHDRAWAL SYNDROME; XEROSTOMIA;

ADRENERGIC ALPHA-AGONISTS; ANALGESICS, NON-NARCOTIC; ANESTHESIA; ANIMALS; DEXMEDETOMIDINE; DRUG INTERACTIONS; HUMANS; HYPNOTICS AND SEDATIVES;

EID: 45949086575     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425255.4.5.619     Document Type: Review

References (68)

1. Payen JF, Chanques C, Mantz J, et al. Current practices in sedation and analgesia for mechanically ventilated critically ill patients: a prospective multicenter patient-based study. Anesthesiology 2007;106:687-95
2. Kollef MH, Ahrens TS, Shannon E. Clinical predictors and outcomes for patients requiring tracheostomy in the intensive care unit. Crit Care Med 1999;27:1714-20
3. Kamibayashi T, Maxe M. Clinical uses of alpha2-adrenergic agonists. Anesthesiology 2000;93:1345-50
4. Wikberg JES, Uhlen S, Chhajlani V. Medetomidine stereoisomers delineate two closely related subtypes of idazoxan (imidazoline) I-receptors in the guinea pig. Eur J Pharmacol 1991;193:335-40
5. Bhana N, Goa KL, McClellan KJ, et al. Dexmedetomidine. Drugs 2000;59:263-8
6. Belleville JP, Ward DS, Bloor BC, et al. Effects of intravenous dexmedetomidine in humans. I. Sedation, ventilation, and metabolic rate. Anesthesiology 1992;77:1125-33
7. Ebert TJ, Hall JE, Barney JA, et al. The effects of increasing plasma concentrations of dexmedetomidine in humans. Anesthesiology 2000;93:382-94
8. Precedex® prescribing information. Hospira, Inc., Lake Forest, IL, 2004
9. Kallio A, Scheinin M, Koulu M, et al. Effects of dexmedetomidine, a selective alpha 2-adrenoceptor agonist, on hemodynamic control mechanisms. Clin Pharmacol Ther 1989;46:33-42
10. Maze M, Bonnet F. Analgesics: receptor ligands. Alpha-2 adrenergic receptor agonists. In: Anesthetic Pharmacology. Physiologic Principles and clinical Practice. A companion to Miller's Anesthesia. Evers AS, Maze M, editors. Elsevier; 2004. p. 473-90
11. Dyck JB, Shafer SL. Dexmedetomidine pharmacokinetics and pharmacodynamics. Anesth Pharm Rev 1993;1:238-45.
12. DeWolf AM, Fragen RJ, Avram MJ, et al. The pharmacokinetics of dexmedetomidine in volunteers with severe renal impairment. Anesth Analg 2001;93:1205-9
13. Diaz SM, Rodarte A, Caparrelli EV. Pharmacokinetics of dexmedetomidine in postsurgical pediatric intensive care unit patients: preliminary study. Pediatr Crit Care Med 2007;8:419-24
14. Petroz GC, Sikich N, James M, et al. A phase I, two-center study of the pharmacokinetics and pharmacodynamics of dexmedetomidine in children. Anesthesiology 2006;105:1098-110
15. Chsysostomou C, Avolio T, Orr R, et al. Dexmedetomidine use in a pediatric cardiac intensive care unit: can we safely use it in infants after cardiac surgery? Pediatr Crit Care Med 2007;8(Suppl 3):A308
16. Mason KP, Zgleszewski SE, Dearden JL, et al. Dexmedetomidine for pediatric sedation for computed tomography imaging studies. Anesth Analg 2006;103:57-62
17. Scheinin H, Jaakola ML, Sjövall S, et al. Intramuscular dexmedetomidine as premedication for general anesthesia: a comparative multicenter study. Anesthesiology 1993;78:1065-75
18. Kharasch ED, Hill HF, Eddy AC. Influence of dexmedetomidine and clonidine on human liver microsomal alfentanil metabolism. Anesthesiology 1991;75:520-4
19. Hammer GB, Drover DR, Cao H. The effects of dexmedetomidine on cardiac electrophysiology in children. Anesth Analg 2008;106:79-83
20. Talke P, Stapelfeldt C, Garcia P. Dexmedetomidine does not reduce epileptiform discharges in adults with epilepsy. J Neurosurg Anesthesiol 2007;19:195-9
21. Enomoto Y, Kudo T, Saito T, et al. Prolonged use of dexmedetomidine in an infant with respiratory failure following living donor liver transplantation. Pediatric Anesthesia 2006;16:1285-8
22. Finkel JC, Jhonson YJ, Quezado ZM. The use of dexmedetomidine to facilitate acute discontinuation of opioids after cardiac transplantation in children. Crit Care Med 2005;33:2110-2
23. Shehabi Y, Ruettimann U, Adamson H, et al. Dexmedetomidine infusion for more than 24 hours in critically ill patients: sedative and cardiovascular effects. Intensive Care Med 2004;30:2188-96
24. Aantaa R, Kanto J, Scheinin M, et al. Dexmedetomidine, an alpha 2-adrenoceptor agonist, reduces anesthetic requirements for patients undergoing minor gynecologic surgery. Anesthesiology 1990;73:230-5
25. Tanskanen PE, Kyttä JV, Randell TT. Dexmedetomidine as an anaesthetic adjuvant in patients undergoing intracranial tumour surgery: a double-blind, randomized and placebo-controlled study. Br J Anaesth 2006;97:658-65
26. Ard JL Jr, Bekker AY, Doyle WK. Dexmedetomidine in awake craniotomy: a technical note. Surg Neurol 2005;63:114-6; discussion 116-7
27. Kobayashi A, Okuda T, Kotani T, Oda Y. Efficacy of dexmedetomidine for controlling delirium in intensive care unit patients. Masui 2007;56:1155-60
28. Pandharipande PP, Pun BT, Herr DL, et al. Effect of sedation with dexmedetomidine vs lorazepam on acute brain dysfunction in mechanically ventilated patients: the MENDS randomized controlled trial. JAMA 2007;298:2644-53
29. Easley RB, Brady KM, Tobias JD. Dexmedetomidine for the treatment of postanesthesia shivering in children. Paediatr Anaesth 2007;17:341-6
30. Venn RM, Grounds RM. Comparison between dexmedetomidine and propofol for sedation in the intensive care unit: Patient and clinician perceptions. Br J Anaesth 2001;87:684-90
31. Triltsch AE, Welte M, von Homeyer P, et al. Bispectral index-guided sedation with dexmedetomidine in intensive care: a prospective, randomized, double blind, placebo-controlled phase II study. Crit Care Med 2002;30:1007-14
32. Tobias JD, Berkenbosch JW. Sedation during mechanical ventilation in infants and children: dexmedetomidine versus midazolam. South Med J 2004;97:451-5
33. Chrysostomou C, Di Filippo S, Manrique A, et al. Use of dexmedetomidine in children after cardiac and thoracic surgery. Pediatr Crit Care Med 2006;7:126-31
34. Walker J, Maccallum M, Fischer C, et al. Sedation using dexmedetomidine in pediatric burn patients. J Burn Care Res 2006;27:206-10
35. Koroglu A, Teksan H, Sagir O, et al. A comparison of the sedative, hemodynamic, and respiratory effects of dexmedetomidine and propofol in children undergoing magnetic resonance imaging. Anesth Analg 2006;103:63-7
36. Berkenbosch JW, Wankum PC, Tobias JD. Prospective evaluation of dexmedetomidine for noninvasive procedural sedation in children. Pediatr Crit Care Med 2005;6:435-9
37. Barton K, Munoz R, Morell VO. Dexmedetomidine as the primary sedative during invasive procedures in infants and toddlers with congenital heart disease. Pediatr Crit Care Med 2008; In press
38. Shukry M, Kennedy K. Dexmedetomidine as a total intravenous anesthetic in infants. Paediatr Anaesth 2007;17:581-3
39. Munro HM, Tirotta CF, Felix DE, et al. Initial experience with dexmedetomidine for diagnostic and interventional cardiac catheterization in children. Paediatr Anaesth 2007;17:109-12
40. Tobias JD. Dexmedetomidine to treat opioid withdrawal in infants following prolonged sedation in the pediatric ICU. J Opioid Manag 2006;2:201-5
41. Baddigam K, Russo P, Russo J, Tobias JD. Dexmedetomidine in the treatment of withdrawal syndromes in cardiothoracic surgery patients. J Intensive Care Med 2005;20:118-23
42. Zub D, Berkenbosch JW, Tobias JD. Preliminary experience with oral dexmedetomidine for procedural and anesthetic premedication. Paediatr Anaesth 2005;15:932-8
43. Anttila M, Penttilä J, Helminen A, et al. Bioavailability of dexmedetomidine after extravascular doses in healthy subjects. Br J Clin Pharmacol 2003;56:691-3
44. Yuen VM, Irwin MG, Hui 2W et al. A double-blind, crossover assessment of the sedative and analgesic effects of intranasal dexmedetomidine. Anesth Analg 2007;105:374-80
45. Talke P, Li J, Jam U, et al. Effects of perioperative dexmedetomidine infusion in patients undergoing vascular surgery. Perioperative Ischemia Research Group. Anesthesiology 1995;82:620-33
46. Ruesch S, Levy JH. Treatment of persistent tachycardia with dexmedetomidine during off-pump cardiac surgery. Anesth Analg 2002;95:316-8
47. Chrysostomou C, Shiderly D, Berry D, et al. Dexmedetomidine, a novel agent for the acute treatment of supraventricular tachyarrhythmias after pediatric cardiac surgery. Crit Care Med 2007;8(Suppl 3):A2
48. Talke P, Bickler PE. Effects of dexmedetomidine on hypoxia-evoked glutamate release and glutamate receptor activity in hippocampal slices. Anesthesiology 1996;85:551-7
49. Ma D, Rajakumaraswamy N, Maze M. Alpha2-adrenoceptor agonists: shedding light on neuroprotection? Br Med Bull 2005;71:77-92
50. Maier C, Steinberg GK, Sun GH, et al. Neuroprotection by the alpha 2-adrenoreceptor agonist dexmedetomidine in a focal model of cerebral ischemia. Anesthesiology 1993;79:306-12
51. Kuhmonen J, Pokorný J, Miettinen R, et al. Neuroprotective effects of dexmedetomidine in the gerbil hippocampus after ransient global ischemia. Anesthesiology 1997;87:371-7
52. Ma D, Hossain M, Rajakumaraswamy N, et al. Dexmedetomidine produces its neuroprotective effect via the alpha 2A-adrenoceptor subtype. Eur J Pharmacol 2004;502:87-97
53. Dasta JF, Jacobi J, Sesti AM, McLaughlin TP. Addition of dexmedetomidine to standard sedation regimens after cardiac surgery: an outcomes analysis. Pharmacotherapy 2006;26:798-805
54. Ramsay MA, Luterman DL. Dexmedetomidine as a total intravenous anesthetic agent. Anesthesiology 2004;101:787-90
55. Kress JP, Pohlman AS, O'Connor MF, et al. Daily interruption of sedative infusions in critically ill patients undergoing mechanical ventilation. N Engl J Med 2000;342:1471-7
56. Arain SR, Ruehlow RM, Uhrich TD, et al. The efficacy of dexmedetomidine versus morphine for postoperative analgesia after major inpatient surgery. Anesth Analg 2004;98:153-8
57. Taghinia AH, Shapiro FE, Slavin SA. Dexmedetomidine in aesthetic facial surgery: improving anesthetic safety and efficacy. Plast Reconstr Surg 2008;121:269-76
58. Goksu S, Arik H, Demiryurek S, et al. Effects of dexmedetomidine infusion in patients undergoing functional endoscopic sinus surgery under local anaesthesia. Eur J Anaesthesiol 2008;25:22-8
59. Tobias JD. Dexmedetomidine in the treatment of cyclic vomiting syndrome. Paediatr Anaesth 2005;15:709-10
60. Hoffman WE, Kochs E, Werner C, et al. Dexmedetomidine improves neurologic outcome from incomplete ischemia in the rat. Reversal by the alpha 2-adrenergic antagonist atipamezole. Anesthesiology 1991;75:328-32
61. Engelhard K, Werner C, Eberspächer E, et al. The effect of the alpha 2-agonist dexmedetomidine and the N-methyl-D-aspartate antagonist S(+)-ketamine on the expression of apoptosis-regulating proteins after incomplete cerebral ischemia and reperfusion in rats. Anesth Analg 2003;96:524-31
62. Prielipp RC, Wall MH, Tobin JR, et al. Dexmedetomidine-induced sedation in volunteers decreases regional and global cerebral blood flow. Anesth Analg 2002;95:1052-9
63. Drummond JC, Dao AV, Roth DM, et al. Effect of dexmedetomidine on cerebral blood flow velocity, cerebral metabolic rate, and carbon dioxide response in normal humans. Anesthesiology 2008;108:225-32
64. Lawrence CJ, Prinzen FW, de Lange S. The effect of dexmedetomidine on the balance of myocardial energy requirement and oxygen supply and demand. Anesth Analg 1996;82:544-50
65. Wallace AW, Galindez D, Salahieh A, et al. Effect of clonidine on cardiovascular morbidity and mortality after noncardiac surgery. Anesthesiology 2004;101:284-93
66. Wijeysundera DN, Naik JS, Beattie WS. Alpha-2 adrenergic agonists to prevent perioperative cardiovascular complications: a meta-analysis. Am J Med 2003;114:742-52
67. Kulka PJ, Tryba M, Zenz M. Preoperative alpha2-adrenergic receptor agonists prevent the deterioration of renal function after cardiac surgery: results of a randomized, controlled trial. Crit Care Med 1996;24:947-52
68. Frumento RJ, Logginidou HG, Wahlander S, et al. Dexmedetomidine infusion is associated with enhanced renal function after thoracic surgery. J Clin Anesth 2006;18:422-6